Joëlle Guilhot

10.9k total citations · 2 hit papers
129 papers, 4.9k citations indexed

About

Joëlle Guilhot is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Joëlle Guilhot has authored 129 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Hematology, 81 papers in Genetics and 45 papers in Rheumatology. Recurrent topics in Joëlle Guilhot's work include Chronic Myeloid Leukemia Treatments (97 papers), Chronic Lymphocytic Leukemia Research (69 papers) and Eosinophilic Disorders and Syndromes (42 papers). Joëlle Guilhot is often cited by papers focused on Chronic Myeloid Leukemia Treatments (97 papers), Chronic Lymphocytic Leukemia Research (69 papers) and Eosinophilic Disorders and Syndromes (42 papers). Joëlle Guilhot collaborates with scholars based in France, Germany and Netherlands. Joëlle Guilhot's co-authors include François Guilhot, François‐Xavier Mahon, Laurence Legros, Delphine Réa, Gabriel Étienne, Aude Charbonnier, Philippe Rousselot, Franck E. Nicolini, Bruno Varet and Agnès Guerci and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Clinical Nutrition.

In The Last Decade

Joëlle Guilhot

123 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2010 1.0k citations François‐Xavier Mahon, Delphine Réa et al. profile →
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

2016 315 citations Gabriel Étienne, Joëlle Guilhot et al. profile →

Peers

Countries citing papers authored by Joëlle Guilhot

Since Specialization

Citations

This map shows the geographic impact of Joëlle Guilhot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joëlle Guilhot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joëlle Guilhot more than expected).

Fields of papers citing papers by Joëlle Guilhot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joëlle Guilhot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joëlle Guilhot. The network helps show where Joëlle Guilhot may publish in the future.

Co-authorship network of co-authors of Joëlle Guilhot

This figure shows the co-authorship network connecting the top 25 collaborators of Joëlle Guilhot. A scholar is included among the top collaborators of Joëlle Guilhot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joëlle Guilhot. Joëlle Guilhot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy 2020 ·Leukemia Research ·Stina Söderlund, Inger Persson, Mette Ilander, Joëlle Guilhot, Henrik Hjorth‐Hansen, Perttu Koskenvesa, Johan Richter, Susanne Saußele, Satu Mustjoki, Ulla Olsson‐Strömberg	5
2	The Evaluation of Residual Disease By Digital PCR, and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after for Stopping Imatinib First-Line in Chronic Phase CML Patients: Results of the STIM2 Study. 2018 ·Blood ·Franck E. Nicolini, Stéphanie Dulucq, Joëlle Guilhot, Gabriel Étienne, François‐Xavier Mahon	7
3	Advanced Phases at Diagnosis of Childhood Chronic Myeloid Leukemia : The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study) 2017 ·Blood ·Frédéric Millot, Joëlle Guilhot, Meinolf Suttorp, (unknown), (unknown), Petr Sedláček, Eveline S. de Bont, Chi Kong Li, Krzysztof Kałwak, Birgitte Lausen, (unknown), Michael Dworzak, (unknown), Barbara De Moerloose, Roula Farah, Andrea Biondi, André Baruchel	6
4	Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer 2017 ·Clinical Epigenetics ·Emilie Evanno, Julie Godet, (unknown), Joëlle Guilhot, Serge Milin, (unknown), (unknown), Joëlle Roche	43
5	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents 2017 ·Haematologica ·Frédéric Millot, Joëlle Guilhot, Meinolf Suttorp, Adalet Meral Güneş, Petr Sedláček, Eveline de Bont, Chi Kong Li, Krzysztof Kałwak, Birgitte Lausen, (unknown), Michael Dworzak, E Kaiserová, Barbara De Moerloose, (unknown), Andrea Biondi, André Baruchel	38
6	Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort 2015 ·Blood ·Marc Berger, Bruno Pereira, Charlotte Oris, (unknown), Pascale Cony‐Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre‐Barbe, Franck E. Nicolini, Philippe Rousselot, Delphine Réa, Joëlle Guilhot, M. Zénut, Agnès Guerci, Stéphane Giraudier, François‐Xavier Mahon	11
7	Preventing Urinary Incontinence With Supervised Prenatal Pelvic Floor Exercises 2015 ·Obstetrics and Gynecology ·Xavier Fritel, Renaud de Tayrac, Georges Bader, D. Savary, (unknown), X. Deffieux, H. Fernandez, (unknown), Joëlle Guilhot, Arnaud Fauconnier	47
8	Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib 2014 ·Leukemia Research ·Laurence Legros, Joëlle Guilhot, Sébastien Huault, F.-X. Mahon, Claude Preudhomme, François Guilhot, Anne‐Odile Hueber	10
9	Low Natural Killer (NK) Cell Counts and Functionality Are Associated With Molecular Relapse After Imatinib Discontinuation In Patients (pts) With Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) With Undetectable BCR-ABL Transcripts For At Least 2 Years: Preliminary Results From Immunostim, On Behalf Of STIM Investigators 2013 ·Blood ·Nicolas Dulphy, Guylaine Henry, (unknown), Joëlle Guilhot, François Guilhot, Franck E. Nicolini, Laurence Legros, Philippe Rousselot, François‐Xavier Mahon, Antoine Toubert	24
10	Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials 2012 ·Haematologica ·Min Tang, Jasmine Foo, (unknown), Joëlle Guilhot, F.-X. Mahon, Franziska Michor	31
11	Curing Chronic Myeloid Leukemia 2012 ·Current Hematologic Malignancy Reports ·Delphine Réa, Philippe Rousselot, Joëlle Guilhot, François Guilhot, François‐Xavier Mahon	18
12	Long‐term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study 2012 ·American Journal of Hematology ·Philippe Rousselot, Pascale Cony‐Makhoul, Franck E. Nicolini, François Xavier Mahon, Christian Berthou, Delphine Réa, Josy Reiffers, Anne Bornand, Olivier Saint‐Jean, Joëlle Guilhot, François Guilhot, (unknown)	17
13	Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia 2010 ·Haematologica ·Stéphane Flamant, William Ritchie, Joëlle Guilhot, Jeff Holst, Marie Laure Bonnet, Jean‐Claude Chomel, François Guilhot, Ali G. Turhan, John E.J. Rasko	91
14	Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? 2008 ·British Journal of Cancer ·Lucie Karayan‐Tapon, Michel Wager, Joëlle Guilhot, P. Levillain, (unknown), Jonathan Clarhaut, Vincent Potiron, Joëlle Roche	49
15	The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. 2005 ·PubMed ·Joerg Hasford, Markus Pfirrmann, (unknown), Joëlle Guilhot, Rüdiger Hehlmann, François‐Xavier Mahon, Hanneke C. Kluin‐Nelemans, Kazunori Ohnishi, Juan Luis Steegmann, Josef Thaler	10
16	Reply to ‘Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib’ by Pilot et al. 2005 ·Leukemia ·(unknown), Joëlle Guilhot, Géraldine Martineau, François Guilhot	2
17	Correlation of Clinical Features and Methylation Status of MGMT Gene Promoter in Glioblastomas 2004 ·Journal of Neuro-Oncology ·(unknown), Michel Wager, Joëlle Guilhot, Sophie Kusy, B. Bataille, (unknown), F. Lapierre, Christian‐Jacques Larsen, L. Karayan-Tapon	77
18	Expression and Activity of G Protein-Coupled Receptor Kinases in Differentiated Thyroid Carcinoma 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Thierry Métayé, Emmanuelle Menet, Joëlle Guilhot, Jean‐Louis Kraimps	48
19	Study of the variations of the cesarean sections rate in the Rhône–Alpes region (France): Effect of women and maternity service characteristics 1998 ·European Journal of Obstetrics & Gynecology and Reproductive Biology ·Muriel Rabilloud, René Écochard, Joëlle Guilhot, (unknown), (unknown), (unknown)	13
20	Yvette Conry, L'introduction du darwinisme en France au XIXe siècle 1976 ·Persée (Ministère de lEnseignement supérieur et de la Recherche) ·Joëlle Guilhot	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact